Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 28

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 28
---
 obtain or retain business.
The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the
corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore
involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries,
the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government
entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. There is no certainty
that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with
all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations
could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those
of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries,
implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions
on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products,
and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees,
and our business, prospects, operating results, and financial condition.

<div align='center'>20</div>

Employees

As of June 30, 2024, we had 25
full-time employees. The Company has streamlined the organization to focus on its oncology therapeutic vaccine and artificial intelligence
driven healthcare technology. The Company has tailored its workforce to focus on these therapies and technology. We believe that we have
good relations with our employees.

Corporate Information

On February 13, 2024, Renovaro Inc. acquired Renovaro
Cube Intl Ltd and its subsidiaries (“Renovaro Cube”), as a wholly owned subsidiary pursuant to a stock purchase agreement.

We trade on the NASDAQ Capital
Market under the ticker “RENB.”

Our website is http://www.renovarobio.com.
We make available free of charge, on or through our website, our annual, quarterly, and current reports and any amendments to those reports
filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as